Eculizumab for aHUS: 24 month predicted versus actual analysis
Page last updated: 2 March 2018
Drug utilisation sub-committee (DUSC)
September 2017
Abstract
Purpose
To report on the use of eculizumab for the treatment of atypical haemolytic uraemic syndrome (aHUS), including a routine 24-month predicted versus actual utilisation analysis.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
1 December 2014
Data Source / methodology
The analyses used data from the Department of Human Services (DHS) supplied prescriptions database for dates of supply up to and including 31 May 2017. Analyses in the report include:
- Count of patients supplied eculizumab by quarter
- New and continuing patient counts by year
- Patient age at initiation
- Patient counts by treatment phase
- Hospital setting
- Prescriber type
- Length of treatment
- A predicted versus actual utilisation analysis for the first two years of listing.
Key Findings
- Use of eculizumab for aHUS in terms of the number of patients, vials and expenditure was more than double what was predicted in both the first and second years of listing.
- Since its listing in December 2014, 145 patients have been supplied eculizumab for aHUS at a cost to Government of $71.5 million (to May 2017).
Full Report
